Silexion Therapeutics Corp - 8-K Filing
Silexion Therapeutics reports Q3 2026 net loss of $2.5 million and announces first patient dosed in SIL204 Phase 2/3 pancreatic cancer trial. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits (d) Exhibits 99)
Tickers: $SLXN
Read the full article at SEC EDGAR
Part of the story Aclaris Therapeutics, Inc. - 8-K Filing (3 articles)